Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$8.85
-8.5%
$10.15
$3.60
$11.99
$123.20M0.4443,284 shs32,633 shs
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$3.10
$4.66
$0.30
$1.47
$105.77M2.6993,510 shsN/A
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
$1.24
$0.95
$3.45
$32.35M1.91715,259 shs2,128 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.57
-5.4%
$2.89
$1.54
$26.96
$9.61M0.54140,143 shs612,890 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-2.53%+13.90%+35.42%+19.51%+78.43%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00%0.00%0.00%0.00%0.00%
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
0.00%0.00%0.00%0.00%0.00%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-5.42%-20.10%-55.90%-75.08%-91.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
4.4322 of 5 stars
3.53.00.04.41.12.51.3
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.8069 of 5 stars
3.52.00.04.62.43.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
3.00
Buy$12.0035.59% Upside
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00
N/AN/AN/A
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
0.00
N/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.334,507.22% Upside

Current Analyst Ratings Breakdown

Latest CSBR, PSTI, XFOR, and ERYP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$50.15M2.44N/AN/A($0.14) per share-63.21
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$32.66M3.24N/AN/A$0.80 per share3.88
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
$20K0.00N/AN/A$1.80 per share0.00
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M3.55N/AN/A$3.90 per share0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$7.28M-$0.0620.11N/A10.97%656.65%24.04%N/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
-$240KN/A0.00N/AN/AN/AN/AN/A
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
-$49.87M-$1.47N/AN/AN/AN/A-100.63%-55.46%N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.73N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest CSBR, PSTI, XFOR, and ERYP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/A
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.99
0.99
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.32
3.65
3.65
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
0.57
8.22
8.22
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
1.09%
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
16.94%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
46.98%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
1.94%
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
5.40%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.83 million7.33 millionOptionable
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
4934.12 million33.46 millionNot Optionable
Pluristem Therapeutics Inc. stock logo
PSTI
Pluristem Therapeutics
15332.35 million30.60 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?
X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

ERYTECH Pharma stock logo

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Pluristem Therapeutics stock logo

Pluristem Therapeutics NASDAQ:PSTI

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.57 -0.09 (-5.42%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.66 +0.09 (+5.73%)
As of 06:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.